Valuation: Acrux Limited

Market Cap 5.9M 4.21M 3.64M 3.44M 3.12M 5.85M 403M 41.11M 15.81M 205M 15.8M 15.45M 652M P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 6.71M 4.79M 4.14M 3.92M 3.55M 6.66M 459M 46.77M 17.99M 233M 17.97M 17.58M 742M EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
95.37%
Yield 2025 *
-
Yield 2026 -

Last Transcript: Acrux Limited

1 week-9.09%
Current month-4.76%
3 months-41.18%
6 months-16.67%
Current year-33.33%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.13
10 years 0.01
Extreme 0.009
0.38
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 24/08/2026
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-9.09%-33.33%-76.74% 4.21M
+1.01%-0.61%+15.09%+61.50% 45.9B
-4.55%-6.60%+28.67%+95.78% 38.7B
+0.77%-1.77%+7.06%+72.13% 11.43B
+0.52%-0.37%-12.89%+9.47% 11.38B
-0.95%0.00%+19.82%+146.45% 9.09B
-0.55%+0.48%+27.74%+36.57% 7.3B
+1.61%-1.03%+16.03%+183.01% 6.98B
-1.00%-0.98%+33.68%-20.38% 7.13B
-2.15%-4.76%-44.26%+4.59% 4.89B
Average -0.53%-2.02%+5.76%+51.24% 14.28B
Weighted average by Cap. -0.94%-2.68%+15.79%+71.53%

Financials

2025 2026
Net sales 4.49M 3.2M 2.77M 2.62M 2.37M 4.45M 307M 31.29M 12.04M 156M 12.02M 11.76M 496M 6.58M 4.69M 4.07M 3.84M 3.48M 6.53M 450M 45.87M 17.65M 228M 17.63M 17.24M 728M
Net income -5.94M -4.24M -3.67M -3.47M -3.14M -5.9M -407M -41.44M -15.94M -206M -15.93M -15.57M -658M -604K -431K -373K -353K -319K -599K -41.32M -4.21M -1.62M -20.95M -1.62M -1.58M -66.82M
Net Debt 2.77M 1.98M 1.71M 1.62M 1.47M 2.75M 190M 19.32M 7.43M 96.15M 7.43M 7.26M 307M 813K 580K 502K 475K 430K 807K 55.62M 5.67M 2.18M 28.2M 2.18M 2.13M 89.94M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
16/09/26 A$0.0100 0.00% 1,000,000
15/09/26 A$0.0100 -9.09% 325,000
09/09/26 A$0.0110 0.00% 2,843,866
08/09/26 A$0.0110 0.00% 388,905

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!